Tarsus Pharmaceuticals (TARS) Retained Earnings (2019 - 2026)

Tarsus Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at $782.8 million for Q1 2026.

• On a quarterly basis, Retained Earnings rose 303.16% year-over-year to $782.8 million in Q1 2026; TTM through Mar 2026 was $782.8 million, a 303.16% increase from a year earlier, with the FY2025 full-year figure at $381000.0, down 99.93% from the prior year.
• Retained Earnings climbed to $782.8 million in Q1 2026 per TARS's latest filing, from $381000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $782.8 million in Q1 2026 and bottomed at -$385.3 million in Q1 2025.
• The 5-year median for Retained Earnings is $381000.0 (2025), against an average of $159.4 million.
• Across the five-year window, Retained Earnings soared 1924.32% in 2022 and slumped 1363713.04% in 2024, its largest moves.
• Year by year, Retained Earnings stood at $301.7 million in 2022, then sank by 181.08% to -$244.7 million in 2023, then soared by 338.93% to $584.6 million in 2024, then sank by 99.93% to $381000.0 in 2025, then surged by 205369.29% to $782.8 million in 2026.
• Per Business Quant, the three latest TARS Retained Earnings figures stand at $782.8 million (Q1 2026), $381000.0 (Q4 2025), and $289000.0 (Q3 2025).